glp-1 announcement Medicare to begin covering weight-loss drugs for first time starting July 1 GLP-1 Injections for Medical Weight

Most were similar to adverse effects observed in existing GLP-1 therapies

Ready to revolutionize your career and grow your practice

Onceweekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

(28) GLP-1 users had a lower all-cause mortality rate (18.3 per 10,000 person-years) compared to DPP4-Is (69.9 per 10,000 person-years) and older agents (52.5 per 10,000 person-years)

The comparison is not as simple as "newer is better." Each compound has genuine advantages the other lacks

The most frequently reported clinical outcomes included initial hospitalization or prolonged hospitalization (13.6%) and other serious medical events (12.3%)